Report: Insurers could gain up to $1B in J&J hip settlement deal

Insurers also stand to gain plenty from Johnson & Johnson's ($JNJ) $2.5-billion-plus offer to settle 8,000 lawsuits involving faulty metal hip implants--an offer that is in jeopardy due to patient complaints. In addition to the patient settlement, the health care conglomerate will fork over as much as $1 billion to insurers who covered patients' costs of removing the now-recalled ASR implants, a lawyer involved in the agreement said in a letter obtained by Bloomberg. With that extra cost factored in, Johnson & Johnson's DePuy division, which sold the implants, could end up paying more than $4 billion to deal with all of the settlement's various pieces factored in, according to the article. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.